Related references
Note: Only part of the references are listed.Biologics in the treatment of asthma in children and adolescents
Leonard B. Bacharier et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to- Severe Asthma
Ian D. Pavord et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)
Determinants of lung function across childhood in the Severe Asthma Research Program (SARP) 3
Jonathan M. Gaffin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)
TH17 cells and corticosteroid insensitivity in severe asthma
Yan Xie et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Biologic Therapies for Severe Asthma
Guy G. Brusselle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma
Ian D. Pavord et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
Difficult-to-Treat Asthma Management in School-Age Children
Andy Bush et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial
Daniel J Jackson et al.
LANCET (2022)
The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma
Laurits Frossing et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation
Katrien Eger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Leonard B. Bacharier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST
Jorge F. Maspero et al.
ALLERGY (2021)
Atopic Dermatitis
Sonja Staender
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Andrew Menzies-Gow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
Joseph K. Han et al.
LANCET RESPIRATORY MEDICINE (2021)
Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma
Xingnan Li et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Serum IL-6: A biomarker in childhood asthma?
Daniel J. Jackson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Children with severe persistent asthma have disparate peripheral blood and lower airway eosinophil levels
Victoria Ribeiro et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children
Matthew C. Altman et al.
NATURE IMMUNOLOGY (2019)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert et al.
LANCET (2019)
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Steven W. Yancey et al.
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2019)
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies
Danielle C. M. Belgrave et al.
LANCET RESPIRATORY MEDICINE (2018)
Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life
Dinh S. Bui et al.
LANCET RESPIRATORY MEDICINE (2018)
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
Eugene R. Bleecker et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience
Bradley E. Chipps et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
A Distinct Low Lung Function Trajectory from Childhood to the Fourth Decade of Life
Cristine E. Berry et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach
Cara J. Bossley et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study
Phillip L. Lieberman et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Asthma phenotypes in inner-city children
Edward M. Zoratti et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts
Michael C. Peters et al.
LANCET RESPIRATORY MEDICINE (2016)
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
Hector G. Ortega et al.
LANCET RESPIRATORY MEDICINE (2016)
Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations
Stephen J. Teach et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma
N. Ullmann et al.
ALLERGY (2013)
Exploring the Effects of Omalizumab in Allergic Asthma An Analysis of Biomarkers in the EXTRA Study
Nicola A. Hanania et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Reassessment of Omalizumab-Dosing Strategies and Pharmacodynamics in Inner-City Children and Adolescents
Christine A. Sorkness et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2013)
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy A Randomized Trial
Nicola A. Hanania et al.
ANNALS OF INTERNAL MEDICINE (2011)
Heterogeneity of severe asthma in childhood: Confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program
Anne M. Fitzpatrick et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
William W. Busse et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Wendy C. Moore et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma
Jean Bousquet et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
Bob Lanier et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment):: INNOVATE
M Humbert et al.
ALLERGY (2005)
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)
H Milgrom et al.
PEDIATRICS (2001)
Share Paper
